MX2016011825A - Derivado de 1,3-benzodioxol. - Google Patents
Derivado de 1,3-benzodioxol.Info
- Publication number
- MX2016011825A MX2016011825A MX2016011825A MX2016011825A MX2016011825A MX 2016011825 A MX2016011825 A MX 2016011825A MX 2016011825 A MX2016011825 A MX 2016011825A MX 2016011825 A MX2016011825 A MX 2016011825A MX 2016011825 A MX2016011825 A MX 2016011825A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- benzodioxole
- benzodioxole derivative
- Prior art date
Links
- 150000005529 1,3-benzodioxoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 2
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FTNJQNQLEGKTGD-ZFJHNFROSA-N 1,3-benzodioxole Chemical group C1O[13C]=2[13CH]=[13CH][13CH]=[13CH][13C]=2O1 FTNJQNQLEGKTGD-ZFJHNFROSA-N 0.000 abstract 1
- 101001028782 Homo sapiens Histone-lysine N-methyltransferase EZH1 Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un compuesto que tiene una estructura química particular y que tiene un excepcional efecto inhibidor sobre la actividad de EZH1 y/o EZH2 o una sal farmacológicamente aceptable del mismo. Un compuesto que tiene una estructura de 1,3-benzodioxol representado por la fórmula general (I) o una sal farmacológicamente aceptable del mismo, o una composición farmacéutica que comprende el compuesto (R1, R2, R3, R4, R5, R6 y V en la fórmula (I) son cada uno como se definen en la presente memoria descriptiva). (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014053235 | 2014-03-17 | ||
PCT/JP2015/057652 WO2015141616A1 (ja) | 2014-03-17 | 2015-03-16 | 1,3-ベンゾジオキソール誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016011825A true MX2016011825A (es) | 2016-12-16 |
MX370676B MX370676B (es) | 2019-12-19 |
Family
ID=54144584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011825A MX370676B (es) | 2014-03-17 | 2015-03-16 | Derivado de 1,3-benzodioxol. |
Country Status (28)
Country | Link |
---|---|
US (2) | US10017500B2 (es) |
EP (1) | EP3121175B1 (es) |
JP (1) | JP5806438B1 (es) |
KR (1) | KR102302830B1 (es) |
CN (1) | CN106132954B (es) |
AU (1) | AU2015232543B2 (es) |
BR (1) | BR112016020621B1 (es) |
CA (1) | CA2942883C (es) |
CY (1) | CY1122821T1 (es) |
DK (1) | DK3121175T3 (es) |
ES (1) | ES2774900T3 (es) |
HR (1) | HRP20200354T1 (es) |
HU (1) | HUE049417T2 (es) |
IL (1) | IL247836B (es) |
LT (1) | LT3121175T (es) |
MX (1) | MX370676B (es) |
MY (1) | MY192603A (es) |
NZ (1) | NZ723312A (es) |
PH (1) | PH12016501813A1 (es) |
PL (1) | PL3121175T3 (es) |
PT (1) | PT3121175T (es) |
RS (1) | RS60022B1 (es) |
RU (1) | RU2679131C2 (es) |
SG (1) | SG11201607006TA (es) |
SI (1) | SI3121175T1 (es) |
TW (1) | TWI648275B (es) |
WO (1) | WO2015141616A1 (es) |
ZA (1) | ZA201605622B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3121175B1 (en) | 2014-03-17 | 2019-12-04 | Daiichi Sankyo Company, Limited | 1,3-benzodioxole derivatives as ezh1 and/or ezh2 inhibitors |
BR112018001688B1 (pt) * | 2015-07-30 | 2023-05-02 | Daiichi Sankyo Company, Limited | Uso de um composto |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
CN106588914B (zh) * | 2015-10-16 | 2018-11-02 | 陈剑 | 具有取代吡啶并咪唑类衍生物,其制备及其在医药上的应用 |
DK3378859T3 (da) | 2015-11-19 | 2020-01-20 | Jiangsu Hengrui Medicine Co | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin |
WO2017199227A1 (en) | 2016-05-20 | 2017-11-23 | S & I Ophthalmic, Llc. | Process for preparation of 3,4-dihydroxy-2-methyl benzoic acid alkylester |
KR101770302B1 (ko) * | 2016-06-28 | 2017-08-22 | 주식회사 녹십자 | 다이페닐메탄 유도체의 제조방법 |
CN106727556B (zh) * | 2016-11-30 | 2017-10-20 | 鑫喆喆 | 一种治疗脑损伤的药物组合物 |
KR102480808B1 (ko) * | 2016-12-23 | 2022-12-22 | 다이이찌 산쿄 가부시키가이샤 | Tnap 저해 활성을 갖는 술폰아미드 화합물 |
CN110191722B (zh) * | 2017-01-19 | 2022-03-01 | 第一三共株式会社 | 用于治疗htlv-1相关性脊髓病的药物组合物 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
CN110573151A (zh) | 2017-04-26 | 2019-12-13 | 辛辛那提大学 | 用于治疗急性髓性白血病的方法、试剂和组合物 |
BR112019021023A2 (pt) | 2017-05-18 | 2020-05-05 | Jiangsu Hengrui Medicine Co | cristal de base livre de derivado de benzofurano e método de preparação. |
MX2020002944A (es) | 2017-09-14 | 2020-09-28 | Daiichi Sankyo Co Ltd | Compuesto que tiene estructura ciclica. |
AU2018363467B2 (en) | 2017-11-10 | 2023-09-07 | Jiangsu Hengrui Medicine Co., Ltd. | Method for preparing benzofuran derivative |
JP7025556B2 (ja) | 2018-01-31 | 2022-02-24 | ミラティ セラピューティクス, インコーポレイテッド | Prc2阻害剤 |
SG11202009438UA (en) * | 2018-04-18 | 2020-11-27 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP3797108B1 (en) * | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN113480525B (zh) * | 2018-07-27 | 2024-02-27 | 苏州信诺维医药科技股份有限公司 | 多取代苯环化合物、制备方法及其用途 |
CA3121441C (en) | 2018-11-29 | 2023-08-08 | Daiichi Sankyo Company, Limited | Ezh1/2 dual inhibitor-containing pharmaceutical composition to be used as a combination drug |
KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
WO2021016414A1 (en) * | 2019-07-24 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
WO2021016409A1 (en) * | 2019-07-24 | 2021-01-28 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition in combination therapies for the treatment of cancers |
JPWO2021025148A1 (es) | 2019-08-08 | 2021-02-11 | ||
US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
TW202144341A (zh) * | 2020-03-13 | 2021-12-01 | 大陸商四川海思科製藥有限公司 | Zeste同源基因增強子2抑制劑及其用途 |
WO2022009911A1 (ja) | 2020-07-08 | 2022-01-13 | 第一三共株式会社 | 1,3-ベンゾジオキソール誘導体の製造方法 |
KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
AU2021203261B1 (en) * | 2020-08-13 | 2021-09-23 | Hanmi Pharmaceutical Co., Ltd. | Novel dioxoloisoquinolinone derivatives and use thereof |
TW202333702A (zh) * | 2021-11-10 | 2023-09-01 | 日商第一三共股份有限公司 | 具有優異溶出性之醫藥組成物 |
CN114149297A (zh) * | 2021-12-07 | 2022-03-08 | 北京中医药大学 | 一种微波辅助的选择性芳基甲醛的绿色合成方法 |
CN116496263A (zh) * | 2022-01-27 | 2023-07-28 | 江苏天士力帝益药业有限公司 | Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用 |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
WO2023217018A1 (zh) * | 2022-05-07 | 2023-11-16 | 贝达药业股份有限公司 | Ezh2抑制剂及其在医药上的应用 |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
CN115974856B (zh) * | 2022-12-28 | 2023-08-11 | 北京康立生医药技术开发有限公司 | 一种治疗成人t细胞白血病淋巴瘤药物伐美妥司他的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
WO2013067302A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
WO2013067296A1 (en) | 2011-11-04 | 2013-05-10 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED | Method of treatment |
US9051269B2 (en) * | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
US20150272939A1 (en) * | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
EP2908843B1 (en) | 2012-11-19 | 2019-09-04 | Agency For Science, Technology And Research | Treating cancer |
EP3121175B1 (en) | 2014-03-17 | 2019-12-04 | Daiichi Sankyo Company, Limited | 1,3-benzodioxole derivatives as ezh1 and/or ezh2 inhibitors |
-
2015
- 2015-03-16 EP EP15765525.9A patent/EP3121175B1/en active Active
- 2015-03-16 LT LTEP15765525.9T patent/LT3121175T/lt unknown
- 2015-03-16 MX MX2016011825A patent/MX370676B/es active IP Right Grant
- 2015-03-16 US US15/123,523 patent/US10017500B2/en active Active
- 2015-03-16 KR KR1020167024813A patent/KR102302830B1/ko active IP Right Grant
- 2015-03-16 MY MYPI2016001687A patent/MY192603A/en unknown
- 2015-03-16 RU RU2016140420A patent/RU2679131C2/ru active
- 2015-03-16 JP JP2015534847A patent/JP5806438B1/ja active Active
- 2015-03-16 HU HUE15765525A patent/HUE049417T2/hu unknown
- 2015-03-16 CN CN201580014878.3A patent/CN106132954B/zh active Active
- 2015-03-16 AU AU2015232543A patent/AU2015232543B2/en active Active
- 2015-03-16 SI SI201531090T patent/SI3121175T1/sl unknown
- 2015-03-16 PL PL15765525T patent/PL3121175T3/pl unknown
- 2015-03-16 RS RS20200240A patent/RS60022B1/sr unknown
- 2015-03-16 BR BR112016020621-5A patent/BR112016020621B1/pt active IP Right Grant
- 2015-03-16 ES ES15765525T patent/ES2774900T3/es active Active
- 2015-03-16 WO PCT/JP2015/057652 patent/WO2015141616A1/ja active Application Filing
- 2015-03-16 TW TW104108302A patent/TWI648275B/zh active
- 2015-03-16 DK DK15765525.9T patent/DK3121175T3/da active
- 2015-03-16 PT PT157655259T patent/PT3121175T/pt unknown
- 2015-03-16 CA CA2942883A patent/CA2942883C/en active Active
- 2015-03-16 NZ NZ72331215A patent/NZ723312A/en unknown
- 2015-03-16 SG SG11201607006TA patent/SG11201607006TA/en unknown
-
2016
- 2016-08-15 ZA ZA2016/05622A patent/ZA201605622B/en unknown
- 2016-09-15 IL IL247836A patent/IL247836B/en active IP Right Grant
- 2016-09-16 PH PH12016501813A patent/PH12016501813A1/en unknown
-
2018
- 2018-06-07 US US16/002,297 patent/US10954219B2/en active Active
-
2020
- 2020-03-03 HR HRP20200354TT patent/HRP20200354T1/hr unknown
- 2020-03-04 CY CY20201100194T patent/CY1122821T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
WO2016011390A8 (en) | Irak4 inhibiting agents | |
MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
PH12017500416A1 (en) | Compounds and compositions as raf kinase inhibitors | |
GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2018009459A (es) | Derivado de sulfonamida y composicion farmaceutica que contiene el mismo. | |
EA201591805A1 (ru) | Оксабицикло [2.2.2] кислоты - модуляторы gpr120 | |
MX2018003554A (es) | Benzamidas sustituidas con isoxazolina y analogos como insecticidas. | |
MX369798B (es) | Derivados macrociclicos de pirimidina. | |
MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
GEP20186910B (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
NZ731607A (en) | Dihydropyrimidin-2- one compounds and medical use thereof | |
MX2018001517A (es) | Derivados sustituidos de guanidina. | |
WO2018039077A8 (en) | Therapeutic compounds | |
PH12020550403A1 (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
PH12016502568B1 (en) | Novel heterocyclic compound | |
MA39877A (fr) | Formes solides d'un composé pharmaceutiquement actif | |
MX2016013684A (es) | Composicion farmaceutica que contiene derivado de hidantoina. | |
MX2019007786A (es) | Compuestos sustituidos de guanidina. | |
WO2016019312A3 (en) | Vmat inhibitory compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |